Boan Biotech Repurchases 1.00 Million H-Shares, Lifting Treasury Stock to 7.40 Million

Bulletin Express

Yesterday

Shandong Boan Biotechnology Co., Ltd. (Boan Biotech) disclosed that on 9 September 2026 it bought back 1.00 million H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 2.825 to HKD 3.100 per share, for a volume-weighted average cost of HKD 2.922 and an aggregate consideration of HKD 2.92 million.

The transaction reduced the company’s outstanding H-shares (excluding treasury shares) to 614.93 million from 615.93 million, while increasing treasury shares to 7.40 million from 6.40 million. Total issued shares remained unchanged at 622.33 million.

The repurchase forms part of a mandate approved on 22 June 2026 authorising Boan Biotech to buy back up to 62.23 million shares. Cumulative repurchases under this mandate now stand at 7.40 million shares, representing 1.19 % of the shares outstanding on the mandate’s approval date.

Under Hong Kong listing rules, Boan Biotech is subject to a 30-day moratorium on new share issues or treasury-share sales, effective until 9 October 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/news/1141019798"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1141019798\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1141019798?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-09 19:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141019798","market":"us","top_or_hot":-1,"title":"Boan Biotech Repurchases 1.00 Million H-Shares, Lifting Treasury Stock to 7.40 Million","media":"Bulletin Express","content":"<p>Shandong Boan Biotechnology Co., Ltd. (Boan Biotech) disclosed that on 9 September 2026 it bought back 1.00 million H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 2.825 to HKD 3.100 per share, for a volume-weighted average cost of HKD 2.922 and an aggregate consideration of HKD 2.92 million.</p>\n<p>The transaction reduced the company’s outstanding H-shares (excluding treasury shares) to 614.93 million from 615.93 million, while increasing treasury shares to 7.40 million from 6.40 million. Total issued shares remained unchanged at 622.33 million.</p>\n<p>The repurchase forms part of a mandate approved on 22 June 2026 authorising Boan Biotech to buy back up to 62.23 million shares. Cumulative repurchases under this mandate now stand at 7.40 million shares, representing 1.19 % of the shares outstanding on the mandate’s approval date.</p>\n<p>Under Hong Kong listing rules, Boan Biotech is subject to a 30-day moratorium on new share issues or treasury-share sales, effective until 9 October 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Boan Biotech Repurchases 1.00 Million H-Shares, Lifting Treasury Stock to 7.40 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBoan Biotech Repurchases 1.00 Million H-Shares, Lifting Treasury Stock to 7.40 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-09 19:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shandong Boan Biotechnology Co., Ltd. (Boan Biotech) disclosed that on 9 September 2026 it bought back 1.00 million H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 2.825 to HKD 3.100 per share, for a volume-weighted average cost of HKD 2.922 and an aggregate consideration of HKD 2.92 million.</p>\n<p>The transaction reduced the company’s outstanding H-shares (excluding treasury shares) to 614.93 million from 615.93 million, while increasing treasury shares to 7.40 million from 6.40 million. Total issued shares remained unchanged at 622.33 million.</p>\n<p>The repurchase forms part of a mandate approved on 22 June 2026 authorising Boan Biotech to buy back up to 62.23 million shares. Cumulative repurchases under this mandate now stand at 7.40 million shares, representing 1.19 % of the shares outstanding on the mandate’s approval date.</p>\n<p>Under Hong Kong listing rules, Boan Biotech is subject to a 30-day moratorium on new share issues or treasury-share sales, effective until 9 October 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06955","symbol_name":"博安生物","start_time":0,"source_url":"","article_id":"1141019798","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141019798","pubTimestamp":1788954075,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shandong Boan Biotechnology Co., Ltd. (Boan Biotech) disclosed that on 9 September 2026 it bought back 1.00 million H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 2.825 to HKD...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06955":"博安生物"},"translate_title":"博安生物回购100万股H股，库存股增至740万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06955":1},"content_text":"Shandong Boan Biotechnology Co., Ltd. (Boan Biotech) disclosed that on 9 September 2026 it bought back 1.00 million H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 2.825 to HKD 3.100 per share, for a volume-weighted average cost of HKD 2.922 and an aggregate consideration of HKD 2.92 million.\nThe transaction reduced the company’s outstanding H-shares (excluding treasury shares) to 614.93 million from 615.93 million, while increasing treasury shares to 7.40 million from 6.40 million. Total issued shares remained unchanged at 622.33 million.\nThe repurchase forms part of a mandate approved on 22 June 2026 authorising Boan Biotech to buy back up to 62.23 million shares. Cumulative repurchases under this mandate now stand at 7.40 million shares, representing 1.19 % of the shares outstanding on the mandate’s approval date.\nUnder Hong Kong listing rules, Boan Biotech is subject to a 30-day moratorium on new share issues or treasury-share sales, effective until 9 October 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}